Thyroid Biology and Disease

SAT-381 - Heart Failure with Reduced Ejection Fraction Is Strongly Associated with Poor Prognosis in Thyroid Storm

Saturday, June 13, 2026

9:30 AM - 4:30 PM CT

Location: ENDOExpo; Poster Floor

Abstract Poster Presenter(s)

Takashi Akamizu, MD, PhD

Pesident
KUMA BYOIN
Kobe, Japan

Senior Author/Primary Investigator(s)

Takashi Akamizu, MD, PhD

Pesident
KUMA BYOIN
Kobe, Japan

Co-Author(s)

MI

Moritake Iguchi, n/a

National Hospital Organization Kyoto Medical Center
Kyoto, Japan
YF

Yasushi Furukawa, n/a

Wakayama Medical University
Wakayama, United States
KT

Keiko Tanaka, n/a

Ehime University Graduate School of Medicine
Matsuyama, United States
OI

Osamu Isozaki, n/a

Wakamatsukawada Clinic
Tokyo, Japan
AS

Atsushi Suzuki, n/a

Fujita Health University School of Medicine
Aichi, Japan
TI

Tadao Iburi, n/a

Takashimadaira Chuo General Hospital
Tokyo, Japan
KT

Kumiko Tsuboi, n/a

Fukushima Medical University
Fukushima, Japan
NK

Naotetsu Kanamoto, n/a

National Hospital Organization Kyoto Medical Center
Kyoto, Japan
KM

Kanshi Minamitani, n/a

Teikyo University Chiba Medical Center
Chiba, Japan
SW

Shu Wakino, n/a

Tokushima University Graduate School of Biomedical Sciences
Tokushima, Japan
ST

Satoshi Teramukai, n/a

Kyoto Prefectural University of Medicine
Kyoto, Japan
EK

Eizen Kimura, n/a

Ehime University Graduate School of Medicine
Matsuyama, Japan
YM

Yoshihiro Miyake, n/a

Ehime University Graduate School of Medicine
Matsuyama, Japan

Disclosure(s):

Takashi Akamizu, MD, PhD: No financial relationships to disclose

Context: The prospective multicenter registry–based study revealed that only lower left ventricular ejection fraction (LVEF) was independently associated with poor prognosis of thyroid storm (TS) on both days 30 and 180 after admission.

Objective: To investigate the management of cardiac complications and their associations with prognosis in TS patients.

Design: A multicenter registry-based study
Patients and

Methods: Patients with TS whose data were reported between 2018 and 2022 in a prospective multicenter registry-based study conducted in Japan. We evaluated LVEF, N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, the use of beta-adrenergic receptor antagonists (beta-AAs), and their associations with mortality and incidence of sequelae.

Results: Among the 109 patients with TS, 55 (50.1%) had concomitant heart failure (HF) at admission. The patients with HF were older and had a higher prevalence of atrial fibrillation, multiple organ failure, and disseminated intravascular coagulation. They also exhibited a higher incidence of poor prognosis (death or sequelae). In patients with HF with reduced ejection fraction (HFrEF) (LVEF < 40%), poor prognosis occurred more often than in patients with HF with preserved ejection fraction (HFpEF) (LVEF ≥ 40%). Furthermore, a lower LVEF was significantly associated with poor prognosis (P < .001). Patients with higher NT-proBNP levels also tended to have a higher incidence of poor prognosis. Beta-AAs were prescribed to most patients, with ultra-short-acting agents being the most commonly administered in patients with HF.

Conclusions: HFrEF is strongly associated with poor prognosis in patients with TS. Measuring LVEF is essential for managing patients with TS.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*